MAP4K3-DT

Across TCGA pan-cancer cohorts, MAP4K3-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MAP4K3-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MAP4K3-DT RNA is repressed in tumor relative to normal tissue. In most cancer types MAP4K3-DT is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, THCA, and KICH are the cancer types where MAP4K3-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP4K3-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.592	<.001	11	view →
THCA	Female	II,III,IV	−0.551	<.001	11	view →
KICH	Female	All	−1.074	<.001	7	view →
LUSC	All	All	−0.370	<.001	7	view →
KIRP	Male	All	−0.634	<.001	6	view →
UCEC	All	All	−0.406	<.001	6	view →
LIHC	All	All	+0.379	<.001	5	view →
BLCA	Female	IV	+0.859	<.001	4	view →
BRCA	All	All	−0.228	<.001	4	view →
CHOL	All	All	+1.492	.001	2	view →
PRAD	All	All	+0.379	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MAP4K3-DT–KIRC

Open the KIRC breakdown →